Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Human immunodeficiency virus type 1 (HIV-1) seronegative at screening and enrollment~* Not pregnant or breastfeeding females~* Agrees to protocol-defined method of contraception~* Abstinence from insertion of anything in rectum (eg, medication, enema, penis, or sex toy) for 72 hours before and 72 hours after each rectal biopsy visit~* Abstinence from insertion of anything in vagina (eg, tampon, medication, douche, penis, or sex toy) for 72 hours before and 72 hours after each cervical and vaginal biopsy visit~Exclusion Criteria:~* Post-exposure prophylaxis for HIV exposure within 6 months prior to screening and known HIV-infected partners~* Use of systemic immunomodulatory medications within the 4 weeks prior to the enrollment~* Use of vaginally or rectally administered medications or products (including condoms) containing Nonoxynol-9 (N-9) within the 4 weeks prior to the enrollment~* Abnormalities of the cervical, vaginal, or colorectal mucosa, or significant symptom(s), which in the opinion of the clinician represents a contraindication to protocol-required biopsies~* History of recurrent urticaria~* History of or electrocardiogram demonstrating prolonged QT interval~* History of significant gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1A (Type: EXPERIMENTAL): Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
- Arm 1B (Type: EXPERIMENTAL): Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
- Arm 2A (Type: EXPERIMENTAL): Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
- Arm 2B (Type: EXPERIMENTAL): Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
- Arm 3A (Type: EXPERIMENTAL): Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
- Arm 3B (Type: EXPERIMENTAL): Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
- Arm 4A (Type: EXPERIMENTAL): Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
- Arm 4B (Type: EXPERIMENTAL): Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
- Arm 5A (Type: EXPERIMENTAL): Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
- Arm 5B (Type: EXPERIMENTAL): Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete